Please login to the form below

Not currently logged in
Email:
Password:

IFPMA appoints director general

Thomas Cueni brings expertise from Interpharma and EFPIA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has selected Thomas Cueni as its new director general.

Cueni takes on responsibility for representing the interests of the research-based pharma industry at a global level, working with organisations and governments to promote the value of pharmaceutical innovation and improve access to treatments.

He brings considerable experience as secretary general of Interpharma, the Basel-based association representing Swiss pharma firms, during which time he had been closely associated with IFPMA as a member of its council.

Cueni also brings industry expertise from the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he served in a policy-shaping and advocacy capacity.

Ian Read, IFPMA's president and chief executive and chairman of Pfizer, said: “Thomas has extensive experience in the research-based biopharmaceutical industry and a deep understanding of what is needed to support the continued discovery and development of important life-saving and life-enhancing medicines and vaccines.

“I look forward to working closely with Thomas in advocating for sustainable health policies that foster innovation and ensure patient access to these important advances.”

8th February 2017

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics